logo
Share SHARE
FONT-SIZE Plus   Neg

Halozyme Therapeutics Inc. (HALO) Climbed Sharply Following Upgrade

BMO Capital Markets upgraded its rating on shares of Halozyme Therapeutics Inc. (HALO) Monday to "Outperform" from "Market Perform."

Halozyme Therapeutics gapped up sharply Monday and climbed throughout the first 2 hours of trade. The stock finished up by 1.13 at $8.34 on above average volume and leaped to nearly a 4-month high.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

comments powered by Disqus
RELATED NEWS
Trade HALO now with 
Follow RTT